Strong and healthy muscles are a key factor in mobility, quality of life and healthy aging. But while many processes in the human body can now be measured precisely, muscles often remain a black box. Munich-based medtech startup Noxon wants to change that – and has secured several million euros in seed financing to further develop its technology.
The round is led by High-Tech Gründerfonds. Bayern Kapital, Auxxo and another institutional investor are also participating. The financing was arranged with the support of the BayStartUP investor network.
Making muscle activity visible – even outside the clinic
More than a billion people worldwide live with muscle disorders. However, muscle activity has so far only been recorded sporadically and under clinical conditions – for example, in cases of Parkinson's disease, scoliosis or during rehabilitation after an accident or stroke. Continuous data from everyday life is often lacking.
This means that it often remains unclear whether muscles are working at the right time, are being activated with the appropriate intensity and how they interact with other muscle groups.
This information gap makes it difficult to provide targeted, long-term optimized therapy.
A muscle-computer interface for personalized therapy
Noxon has developed a non-invasive muscle-computer interface that continuously records muscle signals and makes them therapeutically usable. Sensors integrated into clothing measure muscle activity directly and translate it into usable data.
This makes muscle work systematically accessible outside of rehabilitation centers or hospitals for the first time – and can serve as a basis for therapy, training, and prevention. Treatments can thus be personalized, adapted throughout the entire course and optimized not only during individual appointments.
The company's vision: to make muscle therapy data-based, transparent and suitable for everyday use.
Seed financing enables clinical validation and market entry
The seed financing now lays the foundation for market entry. The focus is on clinical validation and regulatory approval of the platform, as well as the expansion of standardized therapy modules as a prerequisite for broad application.
Founded in 2022, the company is a spin-off of three renowned universities, including the Karlsruhe Institute of Technology, TUM, and Munich University of Applied Sciences. The founding team combines expertise in neuroscience, medical technology, hardware and software development and AI-based signal processing.
Digital rehabilitation as a growth market for medtech startups
From an investor perspective, Noxon is addressing a fundamental shift in the rehabilitation and neurotechnology market. Digital, outpatient and personalized solutions are gaining in importance – not least due to demographic change and the rise in chronic diseases.
Dr. Lena-Sophie Schütter, Investment Manager at High-Tech Gründerfonds (HTGF), emphasizes the disruptive potential of the solution:
„What convinces me about Noxon is that effective therapy becomes as simple as applying a bandage. The platform gives patients the opportunity to regain mobility and shape their everyday lives independently: from preventing muscle atrophy to reducing tremors in Parkinson's disease. This is a real step forward in terms of quality of life.“
With its wearable platform, which combines continuous measurement and stimulation, Noxon is positioning itself in a growing global market. In addition to neurological and musculoskeletal indications, the technology also opens up potential in prevention and performance optimization.
BayStartUP as a companion in the fundraising process
BayStartUP supported Noxon throughout the entire fundraising process – from pitch preparation and strategic sparring to targeted networking with relevant investors.
Maria Neugschwender, Managing Director at Noxon, says:
„The support we received from BayStartUP was a decisive door opener for us. The network not only established contacts, but also provided us with structured support throughout the entire financing process and played a key role in attracting the right investors for the next phase of growth.“
BayStartUP Managing Director Dr. Carsten Rudolph says:
„Noxon's young founding team combines exceptional interdisciplinary expertise – from neuroscience and medical technology to hardware, software and AI-based signal processing. We have been supporting the company since its early days and are impressed by how consistently this expertise has been translated into a marketable product, resulting in the rapid formation of a strong team of experienced industry experts.“
This example shows how important structured preparation and access to suitable investors are for technology-driven start-ups – especially in capital-intensive areas such as medtech.
DeepTech from Bavaria with an international perspective
Noxon is a prime example of technology-driven start-ups from Bavaria that combine scientific excellence with entrepreneurial scaling. With the current seed financing, the company is taking the decisive step from research to clinical application and market entry.
Are you planning a seed or Series A round yourself?
Your next steps:
Check:
- Is your business model clearly validated?
- Are regulatory requirements strategically planned?
- Is your pitch ready for investors?
- Do you know the right investors for your phase?
Next Step:
Take advantage of our coaching services or apply for the Bavarian Business Plan Competitions. We provide structured support on your path to successful financing.